You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
隴神戎發(300534.SZ):擬收購普安製藥95%股權並募集配套資金 明起復牌
格隆匯 05-12 21:36

格隆匯5月12日丨隴神戎發(300534.SZ)公佈,公司擬以發行股份加支付現金的方式購買甘肅藥業集團和甘肅農墾集團合計持有普安製藥95%股權並募集配套資金具體為:

隴神戎發發行股份購買甘肅藥業集團所持普安製藥44%股權甘肅農墾集團所持普安製藥5%股權,支付現金購買甘肅農墾集團所持普安製藥46%股權。同時擬甘肅國投集團控制的下屬公司甘肅藥業集團、絲路基金、興隴資本發行股份募集配套資金

此次交易完成後,隴神戎發持有普安製藥95%的股份,普安製藥成為隴神戎發控股子公司。

此次募集配套資金以發行股份購買資產為前提條件,但募集配套資金成功與否並不影響發行股份及支付現金購買資產的實施,募集配套資金的最終發行數量將以取得深交所審核通過並經中國證監會予以註冊的數量為準。

普安製藥100%股權的預評估值為44455萬元。此次交易的標的資產為普安製藥95%股權,預評估值為42232.25萬元,最終的交易金額將在標的公司經符合《證券法》規定條件的會計師事務所、評估機構進行審計和評估後,由交易雙方協商確

次交易前,公司從事的主要業務為醫藥產品、醫療產品、保健衞生產品的研究開發;中成藥、保健食品、原料藥的生產和銷售。此次公司擬收購普安製藥,屬於上市公司在原有業務領域的進一步擴展,豐富上市公司產品同時,依託上市公司現有的產品與生產體系,充分發揮上市公司的管理優勢、品牌優勢,憑藉主打產品元胡止痛滴丸積累的推廣經驗和銷售渠道,整合普安制藥的產品線與營銷體系,實現併購協同效應,提高上市公司銷售收入,提升上市公司產品的市場佔有率與可持續發展能力,有利於進一步增強上市公司主營業務的市場競爭力。

經公司向深圳證券交易所申請,公司股票將於2021513日上午開市起復牌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account